Christoph Ohlmeier
Overview
Explore the profile of Christoph Ohlmeier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okami S, Lecomte C, Raad H, Aguila M, Mohrova Z, Takeichi M, et al.
Sci Rep
. 2024 Oct;
14(1):24193.
PMID: 39406947
No abstract available.
2.
Okami S, Ohlmeier C, Takeichi M, Aguila M, Holl K, Michel A, et al.
J Clin Med
. 2024 Jun;
13(11).
PMID: 38892932
Vericiguat was developed to treat patients with heart failure (HF). Currently, limited data are available to characterize vericiguat-treated patients in real-world clinical settings. This retrospective cohort study was done using...
3.
Okami S, Lecomte C, Raad H, Aguila M, Mohrova Z, Takeichi M, et al.
Sci Rep
. 2024 Apr;
14(1):9095.
PMID: 38643208
Currently, the utilization patterns of medications for heart failure (HF) after worsening HF events remain unelucidated in Japan. Here, we conducted a retrospective cohort study evaluating the changes in HF...
4.
Michel A, Lecomte C, Ohlmeier C, Raad H, Basedow F, Haeckl D, et al.
Am J Cardiovasc Drugs
. 2024 Apr;
24(3):409-418.
PMID: 38573461
Background: Data are limited regarding guideline-directed medical therapy (GDMT) treatment patterns in patients with worsening heart failure (HF). Methods: We used administrative claims databases in Germany and the USA to...
5.
Kerwagen F, Ohlmeier C, Evers T, Herrmann S, Bayh I, Michel A, et al.
Eur J Clin Pharmacol
. 2024 Mar;
80(6):931-940.
PMID: 38472389
Purpose: Vericiguat reduced clinical endpoints in patients experiencing worsening heart failure in clinical trials, but its implementation outside trials is unclear. Methods: This retrospective analysis of longitudinally collected data was...
6.
Ohlmeier C, Schuchhardt J, Bauer C, Brinker M, Kong S, Scott C, et al.
Clin Kidney J
. 2023 Dec;
16(12):2461-2471.
PMID: 38046015
Background: Acute kidney injury (AKI) is a common complication after major surgery. This study assessed the risk of developing or worsening of chronic kidney disease (CKD) and other clinical outcomes...
7.
Schild M, Weber V, Thaci D, Kisser A, Galetzka W, Enders D, et al.
Dermatol Ther (Heidelb)
. 2022 Jul;
12(8):1925-1945.
PMID: 35871680
Introduction: Atopic dermatitis (AD) is a common inflammatory skin disease. Many patients are initiating a systemic therapy, if the disease is not adequately controlled with topical treatment only. Currently, there...
8.
Magerl M, Gothe H, Krupka S, Lachmann A, Ohlmeier C
Orphanet J Rare Dis
. 2021 Feb;
16(1):97.
PMID: 33618747
No abstract available.
9.
Mengel E, Gaedeke J, Gothe H, Krupka S, Lachmann A, Reinke J, et al.
PLoS One
. 2020 Dec;
15(12):e0244279.
PMID: 33382737
Background: Lysosomal Storage Diseases (LSD) are rare and multisytemic diseases which are caused by lysosomal enzyme deficiencies leading into accumulation of waste products due to an interruption in the decomposition...
10.
March S, Andrich S, Drepper J, Horenkamp-Sonntag D, Icks A, Ihle P, et al.
Int J Environ Res Public Health
. 2020 Oct;
17(21).
PMID: 33120886
The data linkage of different data sources for research purposes is being increasingly used in recent years. However, generally accepted methodological guidance is missing. The aim of this article is...